Navigation Links
Novel experimental agent is highly active in CLL patients, interim study shows
Date:12/11/2011

COLUMBUS, Ohio An interim analysis of a phase Ib/II clinical trial indicates that a novel experimental agent for chronic lymphocytic leukemia (CLL) is highly active and well tolerated in patients who have relapsed and are resistant to other therapy. The agent, called PCI-32765, is the first drug designed to target Bruton's tyrosine kinase, a protein essential for CLL-cell survival and proliferation. CLL is the most common form of leukemia, with about 15,000 new cases annually in the U.S. About 4,400 Americans die of the disease each year.

Study co-leader Dr. John C. Byrd, director of the division of hematology at Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) is available to discuss the findings that were presented today (12/13) at the 53rd Annual Meeting of the American Society of Hematology in San Diego.

Study co-leader Dr. Susan O'Brien of The University of Texas M.D. Anderson Cancer Center reported the analysis, which involves 61 patients who have relapsed and whose cancer no longer responds to standard CLL therapy. Of these patients, 27 received a drug dose of 420 milligrams (mg) and 34 received a drug dose of 840 mg.

This study found that 70 percent of patients in the 420-mg group had either a complete or partial remission to treatment after 10 months of follow-up.

"These interim findings are truly exciting because they provide additional evidence that PCI-32765 is a highly active oral therapeutic that produces a high rate of durable remissions the remissions last months on end with acceptable toxicity in relapsed and refractory CLL," Byrd says. "These responses last for many months in part because patients are willing to remain on the drug since the side effects are very tolerable," he notes.

Complete remission means there is no detectable CLL anywhere in the body; partial remission means that the individual's disease volume has decr
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NIH grants to Childrens Hospital will advance novel stem cell treatments for blood disorders
2. A novel in vitro model for light-induced wound healing
3. Novel program translates behavioral and social science research into treatments to reduce obesity
4. Reovirus may be a novel approach to prostate cancer treatment
5. Novel stroke treatment passes safety stage of UCI-led clinical trial
6. Novel medical home program for pediatric patients, families cuts ER visits in half
7. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. Novel Method Eyed for Normalizing Blood Sugar
10. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
11. Novel nanoparticles prevent radiation damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 (HealthDay News) -- Sleep apnea may make it ... you parked your car or left your house keys, a ... sleep apnea showed that this ability -- called spatial memory ... (REM) sleep, even when other stages of sleep weren,t affected. ... dreams typically occur. "We,ve shown for the first time ...
(Date:10/31/2014)... lab device to give cancer researchers an unprecedented microscopic ... spread through the body, causing more than 90 percent ... tumor cells travel, the device could uncover new ways ... the university,s Whiting School of Engineering and its Institute ... new system recently in the journal Cancer Research ...
(Date:10/31/2014)... combination that can trigger the self-destruct process in lung ... according to research that will be presented at the ... next week*. , When healthy cells are no longer ... self destruction. But cancer cells swerve away from this ... grow out of control – causing tumours to form. ...
(Date:10/31/2014)... Phoenix, AZ (PRWEB) October 31, 2014 ... off all dental treatments for November. Whether patients simply need ... there is no better time than now to get that ... but many patients put off routine and even essential treatments ... patients can enjoy substantial savings on any treatments offered by ...
(Date:10/31/2014)... 31, 2014 Adults 65 and ... their Medicare coverage during the current open enrollment ... library for step-by-step guidance, the company announced today. ... on choosing the correct Medicare Advantage plan, understanding ... open enrollment. , “With just one month remaining ...
Breaking Medicine News(10 mins):Health News:Sleep Apnea May Steal Some of Your Memory: Study 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 2Health News:Viewing cancer on the move: New device yields close-up look at metastasis 3Health News:Scientists trigger self-destruct switch in lung cancer cells 2Health News:Phoenix Dentist, Dr. Christy, is Now Offering Ten Percent Off On All Dental Treatments for the Month of November 2
... Indian state of Tamil Nadu has decided to transfer the ... for the anti-cancer drug Glivec to the Intellectual Property Appellate ... setback to the pharma multinational. ,For it cannot ... Appellate Board’s ruling too can be challenged it in the ...
... United States, are now spreading their wings with distant shores ... Hopkins clinic will be set up at Tokyo, Japan. ... Japan’s growing discontent with the national health-care system. Accordingly, around ... by caring for an aging population. This has even got ...
... the ultimate cocktail dress: it's made from red wine, smells like ... spilled on it.// ,The fabric is actually the papery ... finds its way in. ,To form the dress, the wet, ... partially dry out. Deflate the doll, and the finished dress comes ...
... towards a successful womb transplant. // ,Four sheep ... reconnected, Swedish scientists say. ,Professor Mats Brannstrom ... - where the same womb is removed and reconnected. ... in the study developed fatal complications and hence it would ...
... circuitry using textile's threads to monitor the medical condition ... ,This may sound complex, but it is a ... ,In 1996, researchers at Georgia Institute of Technology ... with sensors capable of monitoring a patient's heartbeat, temperature ...
... Center for Devices and Radiological Health of the Food and ... Danek to market INFUSE? Bone Graft for use in dental ... FDA as a replacement for autograft in spinal fusion procedures ... ,"FDA approval of INFUSE marks a major step forward ...
Cached Medicine News:Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 2Health News:Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board 3Health News:John Hopkins Hospitals- Now at Tokyo 2Health News:Womb Transplant Pregnancy Success 2
(Date:10/31/2014)... 2014  Encision Inc. (OTCQB:ECIA), a medical device company ... burns in minimally invasive surgery, today announced financial results ... 2014. The Company posted quarterly net revenue ... $414 thousand, or $(0.04) per share. These results compare ... loss of $50 thousand, or $(0.01) per share, in ...
(Date:10/31/2014)... , Oct. 31, 2014 /CNW Telbec/ - Ergoresearch ... its strategic plan, for accelerated growth in terms of ... and revenues reached $17,862,341. Net income amounted to $1,230,153. ... for the first time in the Company,s history. ... Company joined the forces of its subsidiaries, merging in ...
(Date:10/31/2014)... Research and ... the  "Process Validation in the US and EU ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics to include:  ... to Process Validation for Pharmaceutical and Biopharmaceutical Products ... Process Validation Guidance EU Process Validation ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 2Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 3Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 4Results for the fourth quarter and the fiscal year ended June 30, 2014 - Ergoresearch reports solid 2014 annual results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4
... mass index (BMI) should be taken into account when assessing ... Cancer Treatment Centers of America (CTCA), ... of vitamin D compared to non-obese patients. , , ... , The association between vitamin D and obesity remains unsettled ...
... Calif., June 12 Masimo (Nasdaq: MASI ... and Low-Perfusion pulse oximetry, announced today that three new ... Masimo PVI as a noninvasive and continuous measure of ... at the European Society of Anaesthesiology (ESA) Annual Congress ...
Cached Medicine Technology:Researchers Say More Aggressive Vitamin D Supplementation Needed in Obese Cancer Patients 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 2New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 3New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 4New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 5New Studies Presented at European Society of Anaesthesia Further Validate Masimo PVI(TM) for Noninvasive and Continuous Fluid Monitoring 6
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Medicine Products: